Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022)
This week: It’s April 1st, and we’re sharing some bizarre headlines from across the psychedelics space…
Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial
This week: COMPASS Pathways partners with King’s College London and an NHS Trust to launch a mental health centre; harrowing footage emerges from a MAPS trial; and more…
Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine?
This week: As MINDCURE ceases operations we look at how other companies might fare; Terran Biosciences claims to have over 150 patents; and more…
Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum
This week: Oregon’s Psilocybin Advisory Board Chair resigns amid growing tensions and shrinking timeline; three colleges unite to develop psychedelic curriculum for psychiatrists; and more…
Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine
This week: we take a look at a new study that presents positive cost-effectiveness analysis of MDMA-assisted therapy for PTSD; and more…
Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?
This week: we share a sample of our forthcoming resource that will analyse company expenditure by category, starting with R&D; and more…